MabThera®/Rituxan® (rituximab)


MabThera is the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia. MabThera attacks these cells both directly and together with the body’s immune system.

In the United States, Europe and in additional countries, MabThera is approved for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukaemia.

In the United States, Japan and Canada MabThera is marketed as Rituxan.